Literature DB >> 12070710

The role of CD8(+) T cells in immune responses to colorectal cancer.

Liviu V Titu1, John R T Monson, John Greenman.   

Abstract

Cytotoxic T lymphocytes (CTL) are essential effectors of the cell-mediated immune response. The ability of CTL to specifically recognise and lyse malignant cells expressing the relevant surface antigens under optimal in vitro conditions justifies attempts to boost their number and activity through various forms of immunotherapy. Considering the high prevalence of colorectal cancer and poor survival rates for patients with advanced-stage disease, the development of new protocols based on CTL stimulation represents a genuine and promising treatment option. Significant advances in recombinant DNA technology and molecular biology have led to the identification of a number of tumour-associated antigens (TAA). These have served as vaccine constituents and/or stimuli for obtaining CTL used for adoptive immunotherapy after in vitro stimulation and expansion. The present review describes the properties and functions of CTL as effectors of the immune response against tumours, and summarises the known TAA recognised by CTL and the current status of CTL-related immunotherapeutic interventions in colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070710     DOI: 10.1007/s00262-002-0276-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Colorectal cancer: sailing with a T-cell EMAST.

Authors:  Ajay Goel
Journal:  Dig Dis Sci       Date:  2011-12-20       Impact factor: 3.199

2.  Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape.

Authors:  Li Wenbo; Jin Wang
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

3.  Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI.

Authors:  Vanessa Deschoolmeester; Marc Baay; Filip Lardon; Patrick Pauwels; Marc Peeters
Journal:  Cancer Microenviron       Date:  2011-05-27

4.  Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.

Authors:  Adam E Snook; Michael S Magee; Glen P Marszalowicz; Stephanie Schulz; Scott A Waldman
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

Review 5.  Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Authors:  Fabio Grizzi; Gianluca Basso; Elena Monica Borroni; Tommaso Cavalleri; Paolo Bianchi; Sanja Stifter; Maurizio Chiriva-Internati; Alberto Malesci; Luigi Laghi
Journal:  Inflamm Res       Date:  2018-01-10       Impact factor: 4.575

Review 6.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

7.  Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.

Authors:  Vanessa Deschoolmeester; Marc Baay; Eric Van Marck; Joost Weyler; Peter Vermeulen; Filip Lardon; Jan B Vermorken
Journal:  BMC Immunol       Date:  2010-04-12       Impact factor: 3.615

8.  The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer.

Authors:  Imke Atreya; Carl C Schimanski; Christoph Becker; Stefan Wirtz; Heike Dornhoff; Elke Schnürer; Martin R Berger; Peter R Galle; Wolfgang Herr; Markus F Neurath
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

9.  Predictive Values of Postoperative and Dynamic Changes of Inflammation Indexes in Survival of Patients with Resected Colorectal Cancer.

Authors:  Zi-Quan Zhou; Shuo Pang; Xing-Chen Yu; Qi Xue; Hong-Yu Jiang; Xin-Jun Liang; Li Liu
Journal:  Curr Med Sci       Date:  2018-10-20

10.  Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.

Authors:  János Hunyadi; Csilla András; Imre Szabó; János Szántó; Kornélia Szluha; Sándor Sipka; Péter Kovács; Attila Kiss; Gyula Szegedi; István Altorjay; Péter Sápy; Péter Antal-Szalmás; László Tóth; György Fazekas; Éva Rajnavölgyi
Journal:  Pathol Oncol Res       Date:  2013-10-28       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.